纳斯达克：PSTI-GET评级)和库利南肿瘤(纳斯达克：CGEM-GET评级)都是小盘医疗公司，但哪一项业务更优越？我们将根据这两家公司的盈利能力、分析师建议、股息、风险、收益、估值和机构所有权的强弱对它们进行比较。
热门资讯> 正文
对比脊椎干细胞治疗学(纳斯达克：PSTI)和库利南肿瘤学(纳斯达克：CGEM)
2022-07-07 14:22
Pluristem Therapeutics (NASDAQ:PSTI – Get Rating) and Cullinan Oncology (NASDAQ:CGEM – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Earnings and Valuation
收益和估值
Get
到达
Pluristem Therapeutics
脊椎干细胞治疗学
alerts:
警报：
This table compares Pluristem Therapeutics and Cullinan Oncology's revenue, earnings per share and valuation.
该表比较了Pluristem Treateutics和Cullinan Oncology的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluristem Therapeutics | $20,000.00 | 2,037.92 | -$49.87 million | ($1.47) | -0.86 |
| Cullinan Oncology | $18.94 million | 31.75 | -$65.57 million | ($1.77) | -7.59 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 脊椎干细胞治疗学 | $20,000.00 | 2,037.92 | -4,987万美元 | ($1.47) | -0.86 |
| 库利南肿瘤学 | 1894万美元 | 31.75 | -6,557万美元 | ($1.77) | -7.59 |
Pluristem Therapeutics has higher earnings, but lower revenue than Cullinan Oncology. Cullinan Oncology is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pluristem Treateutics的收益比库利南肿瘤公司高，但收入比库利南肿瘤公司低。库利南肿瘤学的市盈率低于Pluristem治疗公司，这表明它目前是两只股票中更负担得起的一只。
Insider & Institutional Ownership
内部人与机构所有权
16.9% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 93.6% of Cullinan Oncology shares are held by institutional investors. 5.4% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 21.8% of Cullinan Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Pluristem Treateutics公司16.9%的股份由机构投资者持有。相比之下，库利南肿瘤学93.6%的股份由机构投资者持有。Pluristem Treateutics 5.4%的股份由公司内部人士持有。相比之下，库利南肿瘤学21.8%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一家公司的长期表现将好于大盘。
Risk and Volatility
风险和波动性
Pluristem Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Cullinan Oncology has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500.
Pluristem Treateutics的贝塔系数为1.91，这意味着其股价的波动性比标准普尔500指数高出91%。相比之下，库利南肿瘤学的贝塔系数为-0.5，这意味着其股价的波动性比标准普尔500指数低150%。
Profitability
盈利能力
This table compares Pluristem Therapeutics and Cullinan Oncology's net margins, return on equity and return on assets.
该表比较了Pluristem Treateutics和Cullinan Oncology的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Pluristem Therapeutics | N/A | -100.63% | -55.46% |
| Cullinan Oncology | N/A | -17.75% | -17.32% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 脊椎干细胞治疗学 | 不适用 | -100.63% | -55.46% |
| 库利南肿瘤学 | 不适用 | -17.75% | -17.32% |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and target prices for Pluristem Therapeutics and Cullinan Oncology, as provided by MarketBeat.com.
这是Pluristem Treateutics和Cullinan Oncology最近的评级和目标价格细目，由MarketBeat.com提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluristem Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Cullinan Oncology | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 脊椎干细胞治疗学 | 0 | 0 | 0 | 0 | 不适用 |
| 库利南肿瘤学 | 0 | 0 | 2 | 0 | 3.00 |
Cullinan Oncology has a consensus target price of $52.00, suggesting a potential upside of 287.19%. Given Cullinan Oncology's higher probable upside, analysts clearly believe Cullinan Oncology is more favorable than Pluristem Therapeutics.
库利南肿瘤学的共识目标价为52美元，暗示潜在涨幅为287.19。考虑到库利南肿瘤学更有可能上行的一面，分析人士显然认为库利南肿瘤学比Pluristem治疗更有利。
Summary
摘要
Cullinan Oncology beats Pluristem Therapeutics on 7 of the 12 factors compared between the two stocks.
在两只股票之间的12个因素中，库利南肿瘤学在7个因素上击败了Pluristem Treateutics。
About Pluristem Therapeutics (Get Rating)
关于多发性骨髓瘤治疗学(获取评级)
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
PluriSTEM治疗公司是一家生物技术公司。它专注于细胞治疗产品和相关技术的研究、开发、临床试验和制造，用于治疗各种缺血、炎症和血液疾病，以及自身免疫性疾病。该公司开发基于胎盘扩大(PLX)的细胞疗法产品，包括用于髋部骨折手术后恢复的PLX-PAD处于第三阶段临床试验；用于治疗与新冠肺炎相关的急性呼吸窘迫综合征的第二阶段临床试验；以及用于治疗类固醇耐药移植物抗宿主疾病的第一/第二阶段临床试验。该公司还开发了PLX-R18，该药物已完成第一阶段临床试验，用于造血细胞移植后不完全的造血恢复，并进行了各种动物实验，以评估PLX-R18治疗急性辐射综合征的效果。该公司拥有在韩国进行PLX-Pad产品临床试验的许可协议。它还有一个合作项目nTRACK，该项目检查干细胞的金纳米颗粒标记；并与NASA的Ames研究中心达成合作协议，评估PLX细胞疗法在预防和治疗太空任务期间引起的医疗疾病方面的潜力。Pluristem治疗公司成立于2001年，总部设在以色列海法。
About Cullinan Oncology (Get Rating)
关于库利南肿瘤学(获取评级)
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
库利南肿瘤公司是一家生物制药公司，专注于为美国的癌症患者开发一系列靶向肿瘤和免疫肿瘤疗法。该公司的主要候选药物是CLN-081，这是一种口服小分子药物，正在进行I/IIa期剂量升级和扩大试验，用于治疗非小细胞肺癌患者。其临床前产品包括用于治疗急性髓细胞白血病的人源化双特异性抗体CLN-049；用于治疗实体肿瘤的单抗CLN-619；用于治疗实体肿瘤的融合蛋白CLN-617；用于治疗B细胞恶性肿瘤的T细胞结合抗体CLN-978；用于阻断PD-1轴并激活肿瘤T细胞上的4-IBB/CD137通路的双特异性融合蛋白Opal；以及靶向衰老和癌症相关蛋白的细胞疗法JADE。该公司与库利南珍珠公司有合作协议，开发、制造和商业化CLN-081和含有CLN-081的产品；以及Adimab，LLC，以发现和/或优化抗体。库利南肿瘤公司成立于2016年，总部设在马萨诸塞州剑桥市。
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《脊髓灰质炎治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收Pluristem治疗公司和相关公司的最新新闻和分析师评级的每日摘要。
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
